




RealRate

PHARMACEUTICAL 2020

Mylan II B V
Rank 197 of 363



The relative strengths and weaknesses of Mylan II B V are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mylan II B V compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Mylan II B V is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 5.4% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	6,757,300
Cost of Goods Sold	7,602,900
Intangible Assets	21,240,500
Liabilities, Current	5,569,100
Liabilities, Non-Current	12,175,100
Other Assets	1,108,100
Other Compr. Net Income	-1,051,000
Other Expenses	-21,400
Other Liabilities	1,627,500
Other Net Income	0
Other Revenues	11,500,500
Property and Equipment	2,149,600
Research and Development	639,900
Selling, General and Administrative Expense	2,563,600

Output Variable	Value in 1000 USD
Assets	31,255,500
Liabilities	19,371,700
Expenses	10,785,000
Revenues	11,500,500
Stockholders Equity	11,883,800
Net Income	715,500
Comprehensive Net Income	190,000
BaseVar	36,981,850
ECR before LimitedLiability	103%
Economic Capital Ratio	233%